

Global Diabetes Market Trends & Future Forecast - Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1

<https://marketpublishers.com/r/G8DC7037EE1EN.html>

Date: June 2009

Pages: 114

Price: US\$ 1,100.00 (Single User License)

ID: G8DC7037EE1EN

Abstracts

“Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1” report published by Renub Research provides an in-depth analysis of the past, present and future prospects. The report has been researched at source globally, country specific and features latest available data covering:

Global Diabetes Drug, Insulin, DPP-IV, GLP-1 Agonists Market and Future Forecast

Region wise Diabetes, Impaired Glucose Tolerance (IGT) Population and Prevalence

Region wise Diabetes Health Expenditure and Mortality

Top 10 Countries Diabetes Population and Future Forecast

Top 5 Countries Diabetes Drug Market and Future Forecast

Top 7 Countries Insulin Market and Future Forecast

Top 6 Diabetes Drug Brands (Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix) data of Past, Present and Future Market

Top 9 Insulin Brands (Novomix, Novorapid, Levemir, Degludec, Degludecplus,

Humalog, Humulin, Apidra, Lantus) data of Past, Present and Future Market

Top 4 DPP-IV Inhibitors (Januvia, Onglyza, Alogliptin, Galvus) data of Past, Present and Future Market

Top 5 GLP-1 Agonists (Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide) data of Past, Present and Future Market

Research Highlights

USA controls more than 50% of the total Diabetes Drug market share in 2009

Global Insulin Market is estimated to reach around US\$ 17 Billion by 2013

China will have the second highest Insulin market share by 2012 replacing Germany

DPP-IV Inhibitors is predicted to be more than US\$ 5 Billion market by 2015

GLP-1 Agonists, market is forecasted to cross US\$ 6 Billion mark by 2015

Novorapid is the blockbuster Insulin of Novo Nordisk it is expected to cross US\$ 3 Billion by 2015.

Yet to launched Degludec and DegludecPlus is expected to be blockbuster Insulin and cross US\$ 4 Billion and US\$ 6 Billion respectively by 2030.

Januvia is proving a blockbuster of DPP – IV Inhibitors segment expected to be more than US\$ 4 Billion by 2017

Last year launched Victoza and yet to be launched Exenatide LAR is going to be blockbuster GLP-1 Agonists

China diabetes drug market has crossed the figure of Yuan 10 Billion by 2009

Japan Insulin market is expected to be more than US\$ 1 Billion by 2010

Key Drugs Analyzed

Diabetes Drug: Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix

Insulin: Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog, Humulin, Apidra, Lantus

DPP-IV Inhibitors: Januvia, Onglyza, Alogliptin, Galvus,

GLP-1 Agonists: Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide

Data Sources

Information and data in this report has been collected from various printable and non-printable sources like Trade Journals, White papers, Online paid databases, News websites, Government Agencies, Magazines, Newspapers and Trade associations. "

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL DIABETES MARKET

- 2.1 Global – Diabetes Drug Market & Future Forecast
- 2.2 Global – Insulin Market & Future Forecast
- 2.3 Global – Diabetes Drug Market Share & Future Forecast of (Brazil, China, Japan, USA, India)
- 2.4 Global – Insulin Market Share & Future Forecast of (Mexico, Germany, Russia, China, Japan, USA, India)
- 2.5 Global – Dipeptidyl Peptidase (DPP – IV) Inhibitors Market & Future Forecast
- 2.6 Global – Glucagon-like Peptide-1(GLP-1) Market & Future Forecast

3. GLOBAL – TOP 6 DIABETES DRUG BRANDS MARKET PERFORMANCE

- 3.1 Avandia – Past & Present Market
- 3.2 Actos – Past, Present & Future Forecast
- 3.3 Amaryl – Past, Present & Future Forecast
- 3.4 Avandamet – Past, Present & Future Forecast
- 3.5 Prandin/Novonorm – Past & Present Market
- 3.6 Starlix – Past, Present & Future Forecast

4. GLOBAL – TOP 9 INSULIN BRANDS MARKET PERFORMANCE

- 4.1 Novomix – Past, Present & Future Forecast
- 4.2 Novorapid – Past, Present & Future Forecast
- 4.3 Levemir – Past, Present & Future Forecast
- 4.4 Degludec – Yet to be Launched - Future Forecast
- 4.5 Degludecplus – Yet to be Launched – Future Forecast
- 4.6 Humalog – Past & Present Market
- 4.7 Humulin – Past & Present Market
- 4.8 Apidra – Past, Present & Future Forecast
- 4.9 Lantus – Past, Present & Future Forecast

5. GLOBAL – DPP-IV INHIBITORS BRANDS MARKET PERFORMANCE

- 5.1 Januvia – Past, Present & Future Forecast

- 5.2 Onglyza – Past, Present & Future Forecast
- 5.3 Alogliptin – Yet to be Launched – Future Forecast
- 5.4 Galvus – Past, Present & Future Forecast
- 5.5 DPP-IV Inhibitors – In Trial Phases

6. GLOBAL – GLP-1 AGONISTS BRANDS MARKET PERFORMANCE

- 6.1 Byetta – Past, Present & Future Forecast
- 6.2 Victoza – Past, Present & Future Forecast
- 6.3 Exenatide LAR – Yet to be Launched – Future Forecast
- 6.4 Syncria – Yet to be Launched – Future Forecast
- 6.5 Taspoglutide – Yet to be Launched – Future Forecast

7. REGIONAL ESTIMATES FOR DIABETES

- 7.1 Diabetes – Population & Prevalence
- 7.2 Impaired Glucose Tolerance (IGT) – Population & Prevalence
- 7.3 Mortality – Due to Diabetes
- 7.4 North America & Caribbean Region
 - 7.4.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
 - 7.4.2 Healthcare Expenditure & Type 1 Diabetes
 - 7.4.3 Mortality
- 7.5 Middle East and North African Region
 - 7.5.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
 - 7.5.2 Healthcare Expenditure & Type 1 Diabetes
 - 7.5.3 Mortality
- 7.6 South-East Asian Region
 - 7.6.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
 - 7.6.2 Healthcare Expenditure & Type 1 Diabetes
 - 7.6.3 Mortality
- 7.7 European Region
 - 7.7.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
 - 7.7.2 Healthcare Expenditures & Type 1 Diabetes
 - 7.7.3 Mortality
- 7.8 South and Central American Region
 - 7.8.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
 - 7.8.2 Healthcare Expenditures & Type 1 Diabetes
 - 7.8.3 Mortality
- 7.9 Western Pacific Region

- 7.9.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
- 7.9.2 Healthcare Expenditures & Type 1 Diabetes
- 7.9.3 Mortality
- 7.10 African Region
 - 7.10.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
 - 7.10.2 Healthcare Expenditure & Type 1 Diabetes
 - 7.10.3 Mortality

8. GLOBAL – TOP 10 DIABETIC COUNTRIES PERFORMANCE

- 8.1 Number of People in Top 10 Diabetic Place
- 8.2 Prevalence of Diabetes in Top 10 Countries
- 8.3 India
 - 8.3.1 Diabetes Population & Future Scenario
 - 8.3.2 India – Diabetes Drug Market & Future Forecast
 - 8.3.3 India-Insulin Market & Future Forecast
- 8.4 China
 - 8.4.1 Diabetes Population & Future Scenario
 - 8.4.2 Diabetes Drug Market & Future Forecast
 - 8.4.3 China Insulin Market & Future Forecast
- 8.5 United States
 - 8.5.1 Diabetes Population & Future Scenario
 - 8.5.2 Diabetes Drug Market & Future Forecast
 - 8.5.3 Insulin Market & Future Forecast
- 8.6 Brazil
 - 8.6.1 Diabetes Population & Future Scenario
 - 8.6.2 Diabetes Drug Market & Future Forecast
- 8.7 Russia
 - 8.7.1 Diabetes Population & Future Scenario
 - 8.7.2 Insulin Market & Future Forecast
- 8.8 Japan
 - 8.8.1 Diabetes Population & Future Scenario
 - 8.8.2 Diabetes Drug Market & Future Forecast
 - 8.8.3 Insulin Market & Future Forecast
- 8.9 Germany
 - 8.9.1 Diabetes Population & Future Scenario
 - 8.9.2 Insulin Market & Future Forecast
- 8.10 Mexico
 - 8.10.1 Diabetes Population & Future Scenario

8.10.2 Insulin Market & Future Forecast

8.11 Indonesia

8.11.1 Diabetes Population & Future Scenario

8.12 Pakistan

8.12.1 Diabetes Population & Future Scenario

List Of Figures

LIST OF FIGURES:

- Figure 2 1: Global – Diabetes Drug Market (Billion US\$), 2005 – 2009
- Figure 2 2: Global – Forecast of Diabetes Drug Market (Billion US\$), 2010 – 2013
- Figure 2 3: Global – Insulin Market (Billion US\$), 2004 – 2009
- Figure 2 4: Global – Forecast of Insulin Market (Billion US\$), 2010 – 2013
- Figure 2 5: Global – Diabetes Drug Market Share of (Brazil, China, Japan, USA, India) (Percent), 2007 – 2009
- Figure 2 6: Global – Forecast of Diabetes Drug Market Share of (Brazil, China, Japan, USA, India) (Percent), 2010 – 2013
- Figure 2 7: Global – Insulin Market Share of (Mexico, Germany, Russia, China, Japan, USA, India) (Percent), 2007 – 2009
- Figure 2 8: Global – Forecast for Insulin Market Share of (Mexico, Germany, Russia, China, Japan, USA, India) (Percent), 2010 – 2013
- Figure 2 9: Global – DPP – IV Inhibitors Market (Million US\$), 2009 – 2015
- Figure 2 10: Global – GLP-1 Market (Million US\$), 2009 – 2015
- Figure 3 1: Global – Avandia Diabetes Drug Brand Sales (Million US\$), 2004 – 2009
- Figure 3 2: Global – Actos Diabetes Drug Sales (Billion US\$), 2005 – 2009
- Figure 3 3: Global – Forecast for Actos Diabetes Drug Sales (Billion US\$), 2010 & 2013
- Figure 3 4: Global – Amaryl Diabetes Drug Sales (Million US\$), 2006, 2007, 2009, & Q1 2010
- Figure 3 5: Global – Forecast for Amaryl Diabetes Drug Sales (Million US\$), 2010 – 2012
- Figure 3 6: Global – Avandamet Diabetes Drug Sales (Million US\$), 2006 – 2009
- Figure 3 7: Global – Forecast for Avandamet Diabetes Drug Sales (Million US\$), 2010 – 2012
- Figure 3 8: Global – Prandin/Novonorm Diabetes Drug Sales (Million US\$), 2007 – 2009
- Figure 3 9: Global – Starlix Diabetes Drug Sales (Million US\$), 2007 – 2009E
- Figure 3 10: Global – Forecast for Starlix Diabetes Drug Sales (Million US\$), 2010 – 2012
- Figure 4 1: Global – NovoMix Insulin Sales (Million US\$), 2005 – 2009
- Figure 4 2: Global – NovoRapid Insulin Sales (Million US\$), 2005 – 2009
- Figure 4 3: Global – Levemir Insulin Sales (Million US\$), 2005 – 2009
- Figure 4 4: Global – Humalog Insulin Sales (Million US\$), 2006 – 2009
- Figure 4 5: Global – Humulin Insulin Brand Sales (Million US\$), 2006 – 2009
- Figure 4 6: Global – Apidra Insulin Sales (Million US\$), 2005 – 2009, Q1 2010
- Figure 4 7: Apidra – Forecast for Insulin Sales (Million US\$), 2009 – 2013
- Figure 4 8: Global – Lantus Insulin Sales (Million US\$), 2006 – 2009, Q1 2010

Figure 4 9: Global – Forecast for Lantus Insulin Sales (Million US\$), 2010 – 2015

Figure 5 1: Global – Januvia DPP-IV Inhibitors Sales (Million US\$), 2007 – 2009

Figure 5 2: Global – Forecast for Januvia DPP-IV Inhibitors Sales (Million US\$), 2010 – 2017

Figure 5 3: Global – Onglyza DPP-IV Inhibitors Sales & Future Forecast (Million US\$), 2009 – 2017

Figure 5 4: Global – Future Forecast for Alogliptin DPP-IV Inhibitors Sale (Million US\$), 2011 – 2017

Figure 5 5: Global – Galvus DPP-IV Inhibitors Sale (Million US\$), 2007 – 2009

Figure 5 6: Global – Future Forecast for Galvus DPP-IV Inhibitors Sale (Million US\$), 2010 – 2012

Figure 6 1: Global – Byetta GLP-1 Sales (Million US\$), 2006 – 2009

Figure 6 2: Global – Forecast for Byetta GLP-1 Sales (Million US\$), 2010 – 2017

Figure 6 3: Global – Victoza GLP-1 Sales & Future Forecast (Million US\$), 2009 – 2017

Figure 6 4: Global – Forecast for Exenatide LAR GLP-1 Sales (Million US\$), 2011 – 2017

Figure 6 5: Global – Forecast for Syncria GLP-1 Sales (Million US\$), 2013 – 2017

Figure 6 6: Global – Forecast for Taspoglutide GLP-1 Sales (Million US\$), 2012 – 2017

Figure 8 1: India – Number of People with Diabetes (Million), 2003, 2007, 2010

Figure 8 2: India – Diabetes Drug Market (Billion INR), 2006 – 2009

Figure 8 3: India – Forecast for Diabetes Drug Market (Billion INR), 2010 – 2014

Figure 8 4: India – Share of Human Insulin Market, Animal Insulin Market & Oral Diabetes Market (in Percent), 2003 & 2007

Figure 8 5: India – Insulin Market (Million INR), 2006 – 2009

Figure 8 6: India – Forecast for Insulin Market (Million INR), 2010 – 2014

Figure 8 7: China – Number of Diabetes Patients (Million), 2003, 2007 & 2010

Figure 8 8: China – Diabetes Drug Market (Billion Yuan), 2006 – 2009

Figure 8 9: China – Forecast for Diabetes Drug Market (Billion Yuan) 2010 – 2014

Figure 8 10: China – Insulin Market (Million Yuan), 2007 – 2009

Figure 8 11: China – Forecast for Insulin Market (Million Yuan), 2010 – 2014

Figure 8 12: USA – Number of Diabetes Patients (Million), 2003, 2006, 2007 & 2010

Figure 8 13: USA – Diabetes Drug Market (Million US\$), 2002 – 2009

Figure 8 14: USA – Forecast for Diabetes Drug Market (Million US\$), 2010 – 2014

Figure 8 15: USA – Insulin Market (Billion US\$), 2003 – 2009

Figure 8 16: USA – Forecast for Insulin Market (Billion US\$), 2010 – 2014

Figure 8 17: Brazil – Diabetes Population (Million), 2003, 2007 & 2010

Figure 8 18: Brazil – Diabetes Drug Market (Million US\$), 2008 – 2013

Figure 8 19: Russia – Number of Diabetes Population (Million), 2005 & 2010

Figure 8 20: Russia – Insulin Market (Million US\$), 2002, 2005 – 2009

- Figure 8 21: Russia – Forecast for Insulin Market (Million US\$), 2010 – 2014
- Figure 8 22: Japan – Number of Diabetes Population (Million), 2003 – 2010
- Figure 8 23: Japan – Diabetes Drug Market (Million US\$), 2002 – 2009
- Figure 8 24: Japan – Forecast for Diabetes Market (Million US\$), 2010 – 2014
- Figure 8 25: Japan – Insulin Market (Million US\$), 1998 – 2009
- Figure 8 26: Japan – Forecast for Insulin Market (Million US\$), 2010 – 2014
- Figure 8 27: Germany – Number of Diabetes Patients (Million), 2003 – 2010
- Figure 8 28: Germany – Insulin Market (Million US\$), 2004 – 2009E
- Figure 8 29: Germany – Forecast for Insulin Market (Billion US\$), 2010 – 2014
- Figure 8 30: Mexico – Number of People with Diabetes (Million), 2003 – 2005, 2007 & 2010
- Figure 8 31: Mexico – Insulin Market (Million US\$), 2004 – 2009E
- Figure 8 32: Mexico – Forecast for Insulin Market (Million US\$), 2010 – 2014
- Figure 8 33: Pakistan – Number of Diabetes Patients (Million), 2003, 2007 & 2010

List Of Tables

LIST OF TABLES:

Table 4 1: Novomix – Forecast for Insulin Sales (Million US\$), 2010 – 2030

Table 4 2: Global – Forecast for NovoRapid Insulin Sales (Million US\$), 2010 – 2030

Table 4 3: Global – Forecast for Levemir Insulin Sales (Million US\$), 2010 – 2030

Table 4 4: Degludec – Forecast for Insulin Sales (Million US\$), 2010 – 2030

Table 4 5: DegludecPlus – Forecast for Insulin Sales (Million US\$), 2010 – 2030

Table 5 1: DPP-4 Inhibitors –In Trial Phase

Table 7 1: Regional – Estimates for (Number of People with Diabetes, Comparative Diabetes Prevalence %) (20-79 years), 2010 and 2030

Table 7 2: Regional – Estimates for (Number of People with IGT, Comparative IGT Prevalence %) (20-79 years), 2010 and 2030

Table 7 3: Regional – Diabetes Mortality (20-79 Years; Thousand), 2010

Table 7 4: North America and Caribbean Region – Population & Adult Population (Million), 2010 & 2030

Table 7 5: North America and Caribbean Region – Number of People with Diabetes & Comparative Prevalence Percent (20-79 Years; Million, Percent), 2010 & 2030

Table 7 6: North America and Caribbean Region – Number of People with IGT & Comparative Prevalence Percent (20-79 Years; Million, Percent), 2010 & 2030

Table 7 7: North America and Caribbean Region – Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030

Table 7 8: North America and Caribbean Region – Diabetes Mortality (20-79 Years; Thousand), 2010

Table 7 9: Middle East and North African Region – Population & Adult Population (Million), 2010 & 2030

Table 7 10: Middle East and North African Region – Number of People with Diabetes & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030

Table 7 11: Middle East and North African Region – Number of People with IGT & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030

Table 7 12: Middle East and North African Region – Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030

Table 7 13: Middle East and North African Region – Diabetes Mortality (20-79 Years; Thousand), 2010

Table 7 14: South-East Asian Region – Population & Adult Population (Million), 2010 & 2030

Table 7 15: South-East Asian Region – Number of People with Diabetes & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030

Table 7 16: South-East Asian Region – Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030

Table 7 17: South-East Asian Region – Diabetes Mortality (20-79 Years; Thousand), 2010

Table 7 18: European Region – Population & Adult Population (Million), 2010 & 2030

Table 7 19: European Region – Number of People with Diabetes & Comparative Prevalence (20-79 Years; Million Percent), 2010 & 2030

Table 7 20: European Region – Number of People with IGT & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030

Table 7 21: European Region – Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030

Table 7 22: European Region – Diabetes Mortality (20-79 Years; Thousand), 2010

Table 7 23: South and Central American Region – Population & Adult Population (Million), 2010 & 2030

Table 7 24: South and Central American Region – Number of People with Diabetes & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030

Table 7 25: South and Central American Region – Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030

Table 7 26: South and Central American Region – Diabetes Mortality (20-79 Years; Thousand), 2010

Table 7 27: Western Pacific Region – Population & Adult Population (Million), 2010 & 2030

Table 7 28: Western Pacific Region – Number of People with Diabetes & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030

Table 7 29: Western Pacific Region – Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030

Table 7 30: Western Pacific Region – Diabetes Mortality (20-79 Years; Thousand), 2010

Table 7 31: African Region – Population & Adult Population (Million), 2010 & 2030

Table 7 32: African Region – Number of People with Diabetes & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030

Table 7 33: African Region – Number of People with IGT & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030

Table 7 34: African Region – Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030

Table 7 35: African Region – Diabetes Mortality (20-79 Years; Thousand), 2010

Table 8 1: Global – Top 10 Countries Number of People with Diabetes (20-79 age group) (Million) 2010 & 2030

Table 8 2: Global – Top 10 Countries in Prevalence of Diabetes (20-79 age group) (Percent), 2010 & 2030

Table 8 3: India – Forecast for Number of People with Diabetes (Million), 2011 – 2030

Table 8 4: China – Forecast for Number of Diabetes Patients (Million), 2011 – 2030

Table 8 5: USA – Forecast for Number of Diabetes Patients (Million), 2011 – 2030

Table 8 6: Brazil – Forecast for Number of Diabetes Population (Million), 2011 – 2030

Table 8 7: Russia – Forecast for Number of Diabetes Population (Million), 2011 – 2030

Table 8 8: Mexico – Forecast for Number of Diabetes Patients (Million), 2011 – 2030

Table 8 9: Indonesia – Forecast for Number of Diabetes Patients (Million), 2010 – 2030

Table 8 10: Pakistan – Forecast for Number of Diabetes Patients (Million), 2011 – 2030

I would like to order

Product name: Global Diabetes Market Trends & Future Forecast - Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1

Product link: <https://marketpublishers.com/r/G8DC7037EE1EN.html>

Price: US\$ 1,100.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G8DC7037EE1EN.html>